Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002421646 | SCV002718834 | uncertain significance | Cardiovascular phenotype | 2022-02-02 | criteria provided, single submitter | clinical testing | The p.G653R variant (also known as c.1957G>A), located in coding exon 11 of the LDB3 gene, results from a G to A substitution at nucleotide position 1957. The glycine at codon 653 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Invitae | RCV003611614 | SCV004551830 | uncertain significance | Myofibrillar myopathy 4 | 2023-02-14 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 653 of the LDB3 protein (p.Gly653Arg). The LDB3 gene has multiple clinically relevant transcripts. This variant occurs in alternate transcript NM_007078.3, and corresponds to NM_001080116.1:c.*19452G>A in the primary transcript. This variant is present in population databases (rs149945820, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with LDB3-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |